Compare · ABT vs AIMD
ABT vs AIMD
Side-by-side comparison of Abbott Laboratories (ABT) and Ainos Inc. (AIMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AIMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $188.12B, about 16679.6x AIMD ($11.3M).
- Over the past year, ABT is down 15.9% and AIMD is down 47.5% - ABT leads by 31.6 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- ABT has more recent analyst coverage (25 ratings vs 0 for AIMD).
- Company
- Abbott Laboratories
- Ainos Inc.
- Price
- $108.08+0.71%
- $1.37-1.44%
- Market cap
- $188.12B
- $11.3M
- 1M return
- +16.58%
- -22.60%
- 1Y return
- -15.93%
- -47.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
Latest AIMD
- SEC Form 424B5 filed by Ainos Inc.
- Ainos Expands Smell AI With Growing Real-World Scent Dataset for Physical AI
- Ainos Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Ainos Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- VASRO Research Highlights Ainos' Expansion of Smell AI Into Patient-Level Breath Intelligence
- Ainos Expands Smell AI Platform into Digital Breath Intelligence Through National Taiwan University Research Program
- Director Chiang Yao-Chung bought $7,175 worth of shares (3,500 units at $2.05) (SEC Form 4)
- Ainos Releases 2026 Mid-Year CEO Letter to Shareholders
- Director Chiang Yao-Chung bought $4,260 worth of shares (2,000 units at $2.13) (SEC Form 4)
- VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations